UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF

THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of Earliest Event Reported): May 19, 2020

Quest Diagnostics Incorporated

(Exact Name of Registrant as Specified in Its Charter)

Delaware

(State or other jurisdiction of incorporation)

001-12215				16-1387862
(Commission File Number)				(I.R.S. Employer Identification No.)
500 Plaza Drive
Secaucus,	NJ			07094
(Address of principal executive offices)				(Zip Code)
		(973)	520-2700
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.01 Par Value	DGX	New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

1

Item 5.07 Submission of Matters to a Vote of Security Holders

(a)           The following is a summary of the voting results for each matter presented to the stockholders at the 2020 Annual Meeting of Stockholders which was held on May 19, 2020.

(b)           The following nominees for the office of director were elected for terms expiring at the 2021 Annual Meeting of Stockholders, by the following votes:

	For		Against		Abstain		Broker Non-Vote
Vicky B. Gregg	111,713,001		383,608		358,033		10,103,251
Wright L. Lassiter, III	111,717,933		211,402		525,307		10,103,251
Timothy L. Main	111,678,010		380,608		396,023		10,103,252
Denise M. Morrison	111,687,298		407,684		359,660		10,103,251
Gary M. Pfeiffer	106,255,022		5,801,710		397,904		10,103,257
Timothy M. Ring	108,986,149		3,071,480		397,009		10,103,255
Stephen H. Rusckowski	104,823,623		6,852,581		778,435		10,103,254
Daniel C. Stanzione	105,222,825		6,837,614		394,202		10,103,252
Helen I. Torley	111,487,576		589,654		377,415		10,103,248
Gail R. Wilensky	107,047,952		5,045,743		360,943		10,103,255

The advisory resolution to approve the executive officer compensation disclosed in the Company’s 2020 Proxy Statement was approved by the following votes:

For		Against		Abstain		Broker Non-Vote
102,689,483		9,258,123		507,022		10,103,265

The ratification of the appointment of the Company’s independent registered public accounting firm for 2020 was approved by the following votes:

For		Against		Abstain
116,451,897		5,625,781		480,215

2

Signature

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

May 21, 2020

QUEST DIAGNOSTICS INCORPORATED

By:    /s/ William J. O'Shaughnessy, Jr.

William J. O'Shaughnessy, Jr.

Secretary

3